Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China flag China · Delayed Price · Currency is CNY
40.10
+0.06 (0.15%)
Oct 30, 2026, 3:04 PM CST

Betta Pharmaceuticals Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Cash & Equivalents
705.76429.98471.68752731.28791.99
Trading Asset Securities
0.666126.440.54-201.01
Cash & Short-Term Investments
706.36495.98598.12752.54731.28993
Cash Growth
43.59%-17.08%-20.52%2.91%-26.36%-35.35%
Accounts Receivable
662.91351.2698.47286.41450.62173.38
Other Receivables
20.5277.951.832.6149.740.75
Receivables
683.43429.21100.3289.02500.32214.13
Inventory
396.13381.16290.09327.5372.17293.32
Prepaid Expenses
---0.2--
Other Current Assets
307.98271.48235.82156.62129.06153.49
Total Current Assets
2,0941,5781,2241,5261,7331,654
Property, Plant & Equipment
2,8652,9623,0092,5742,0561,331
Long-Term Investments
2,0892,5831,4371,382919.27345.79
Goodwill
261.12413.58413.58413.58413.58413.58
Other Intangible Assets
2,6592,6042,7761,9441,2191,183
Long-Term Accounts Receivable
18.8913.289.29---
Long-Term Deferred Tax Assets
58.9459.1356.7339.1385.9655.06
Long-Term Deferred Charges
117.29220.16383.531,2191,4441,252
Other Long-Term Assets
88.5713332.750.339.337.6
Total Assets
10,25110,5669,3429,1477,9106,271

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Accounts Payable
484.43512.32746.11800.1235.85431.19
Accrued Expenses
137.15390.16285.53357.82419.11357.02
Short-Term Debt
-5100.08300.27380.39-
Current Portion of Long-Term Debt
1,194824.19639.85301.25--
Current Portion of Leases
-46.6533.034.64.164.88
Current Income Taxes Payable
121.547.244.260.070.0410.68
Current Unearned Revenue
4.732.372.634.924.460.69
Other Current Liabilities
160.6389.3636.4734.111,26184.4
Total Current Liabilities
2,1021,9171,8481,8032,105888.86
Long-Term Debt
1,2151,5241,5521,816656.03-
Long-Term Leases
66.0662.8471.638.187.36.34
Long-Term Unearned Revenue
234.16226.22150.99144.7112.76112
Long-Term Deferred Tax Liabilities
86.14167.9153.4923.3971.5768.39
Other Long-Term Liabilities
-----510.06
Total Liabilities
3,7033,8983,6763,7952,9521,586

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Common Stock
423.33420.73418.49418.49417.47415.39
Additional Paid-In Capital
2,3282,1642,0762,1421,8601,932
Retained Earnings
3,2713,0562,8342,5032,1812,139
Comprehensive Income & Other
515.83954.47245.21188.3390.9974.64
Total Common Equity
6,5386,5955,5745,2514,8494,561
Minority Interest
9.5572.5392.3100.4108.64124.9
Shareholders' Equity
6,5486,6685,6665,3514,9584,686
Total Liabilities & Equity
10,25110,5669,3429,1477,9106,271

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Total Debt
2,4752,4622,3962,4301,04811.22
Net Cash (Debt)
-1,768-1,966-1,798-1,678-316.59981.77
Net Cash Growth
------35.97%
Net Cash Per Share
-4.19-4.70-4.29-4.00-0.762.36
Filing Date Shares Outstanding
423.33420.73418.49418.49417.47415.39
Total Common Shares Outstanding
423.33420.73418.49418.49417.47415.39
Working Capital
-8.56-339.45-623.63-277.28-371.95765.08
Book Value Per Share
15.4415.6813.3212.5511.6210.98
Tangible Book Value
3,6183,5772,3842,8943,2162,964
Tangible Book Value Per Share
8.558.505.706.927.707.14
Buildings
-3,0412,952586.14585.59627.19
Machinery
-461.18449.64424.26402.25376.01
Construction In Progress
-227.31191.872,0371,448639.67